Competitors see the U.S. approval of Amylin Pharmaceuticals Inc.’s type 2 diabetes drug Bydureon (long-acting exenatide) on Jan. 27 as an event that will boost interest in the entire GLP-1 class, benefiting other agents as well.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?